Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma

NCT06566807 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Marginal Zone Lymphoma

Interventions

DRUG: Orelabrutinib, obinutuzumab

Sponsor

Huai'an First People's Hospital